AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12930428
Drug: Adriamycin 50
RxNorm normalized name: ADRIAMYCIN 50 MG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adriamycin 50 mg
Trial: 3816291
Drug: Trimoprostil 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimoprostil 0.125 mg
Trial: 29174623
Drug: Nonsurgical and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsurgical and noninjection therapies
Trial: 22001391
Drug: Tipifarnib (T)
RxNorm normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tipifarnib (T) 600 mg twice a day × 14 days, Etoposide (E) 100 mg days 1‐3 and 8‐10
Trial: 22001391
Drug: Tipifarnib (T)
RxNorm normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tipifarnib (T) 400 mg twice a day × 14 days, Etoposide (E) 200 mg days 1‐3 and 8‐10
Trial: 19848555
Drug: Tibolone (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone (2.5 mg) plus one Cal+D tablet (500 mg calcium and 200 IU vitamin D) daily
Trial: 19848555
Drug: CEE/MPA (0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE/MPA (0.625 mg conjugated equine estrogen and 2.5 mg medroxyprogesterone acetate) plus one Cal+D tablet daily
Trial: 19848555
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (one Cal+D tablet only)
Trial: 9527081
Drug: Intermittent transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent transdermal nitroglycerin patches (0.4, 0.8, or 1.6 mg/hour)
Trial: 2708843
Drug: Single daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily dose of netilmicin
Trial: 2708843
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily doses of netilmicin
Trial: 24245707
Drug: One-session exposure
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-session exposure treatment (OST)
Trial: 21042231
Drug: 3 injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 injections of TDV at months 0, 3.5, and 12 (TDV-TDV-TDV)
Trial: 21042231
Drug: 1 injection
RxNorm normalized name: vitamin K1 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 injection of yellow fever vaccine (YF) at month 0, and 2 injections of TDV at months 3.5 and 12 (YF-TDV-TDV)
Trial: 21042231
Drug: 3 injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 injections of TDV
Trial: 19296144
Drug: Before-breakfast dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before-breakfast dosing of risedronate 5 mg daily
Trial: 19296144
Drug: Flexible dosing
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible dosing of risedronate 5 mg daily (2 h before and 2 h after any food and drink other than plain water)
Trial: 17134335
Drug: Web administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Web administration of social desirability questionnaires
Trial: 17134335
Drug: Laboratory administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Laboratory administration of social desirability questionnaires
Trial: 17134335
Drug: Self-selected online
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-selected online administration of social desirability questionnaires
Trial: 9060551
Drug: Amoxicillin (2,250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (2,250 mg) + Omeprazole for 14 days
Trial: 8154249
Drug: Biological salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological salt solution (control)
Trial: 3097668
Drug: Oral danazol
RxNorm normalized name: Danazol
DrugBank: Danazol (DB01406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral danazol
Trial: 18996864
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplement (ONS) containing glutamine, carbohydrates, and antioxidants
Trial: 18996864
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplement (ONS)
Trial: 18996864
Drug: Glutamine infusion
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine infusion alone
Trial: 16872926
Drug: Implant-supported prostheses
RxNorm normalized name: LARYNGEAL PROSTHESIS,PROVOX #8273
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-supported prostheses (IP)
Trial: 16872926
Drug: Implants placed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implants placed
Trial: 11078457
Drug: Prolonged hypoglycemia
RxNorm normalized name: Drugs for treatment of hypoglycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged hypoglycemia (2.9 +/‐ 0.1 mmol/l for 30 min)
Trial: 11078457
Drug: Short-duration hypoglycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-duration hypoglycemia (2.9 +/‐ 0.1 mmol/l for 5 min)
Trial: 11078457
Drug: Day 1
RxNorm normalized name: New Day 1.5mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1 euglycemia (5.2 +/‐ 0.1 mmol/l)
Trial: 11078457
Drug: Intermediate-duration hypoglycemia
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate-duration hypoglycemia (2.9 +/‐ 0.1 mmol/l for 30 min)
Trial: 10165528
Drug: Standard intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intravenous (i.v.) antibacterial therapy
Trial: 10165528
Drug: Abbreviated regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abbreviated regimen of intravenous antibacterials for 2 to 4 days followed by oral ciprofloxacin or oral enoxacin
Trial: 25312446
Drug: Switch therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch therapy
Trial: 7934684
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine 150 micrograms/10 ml
Trial: 3728446
Drug: Self-administered mailed
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered mailed questionnaire
Trial: 27938990
Drug: Low-Energy Linear
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Energy Linear Shockwave Therapy (LLi‐ESWT) once a week for 5 weeks
Trial: 27938990
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment once a week for 5 weeks
Trial: 27938990
Drug: Low-Energy Linear
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Energy Linear Shockwave Therapy (LLi‐ESWT) after a 4-week break, once a week for 5 weeks
Trial: 27938990
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment after a 4-week break, once a week for 5 weeks
Trial: 27938990
Drug: Low-Energy Linear
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Energy Linear Shockwave Therapy (LLi‐ESWT)
Trial: 23862237
Drug: Compound Xuanju
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Xuanju Capsule + Tamsulosin Hydrochloride
Trial: 23862237
Drug: Quinolinone antibiotics
RxNorm normalized name: quinoline yellow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinolinone antibiotics + Tamsulosin Hydrochloride
Trial: 19558835
Drug: Local and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local and general dexamethasone administration
Trial: 19558835
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone injection
Trial: 16925616
Drug: Non-pharmacological treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-pharmacological treatments
Trial: 15191380
Drug: Albendazole 10
RxNorm normalized name: albendazole 100 % MISCELL POWDER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole 10 mg/kg for 5 days
Trial: 15191380
Drug: Metronidazole 20
RxNorm normalized name: metronidazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 20 mg/kg daily in three doses for 7 days
Trial: 11465638
Drug: 450 mg
RxNorm normalized name: aspirin 450 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg moclobemide during the first week, and 600 mg afterwards
Trial: 9157942
Drug: 4 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/d of eicosapentaenoic and docosahexaenoic acids (fish oil)
Trial: 8354983
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment with beta blockers and diuretics for a mean follow-up of 25 months
Trial: 3440385
Drug: 24 hours
RxNorm normalized name: PATCH, TRANSDERMAL 24 HOURS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 hours of oxygen administration
Trial: 3440385
Drug: 12 hours
RxNorm normalized name: PATCH, TRANSDERMAL 12 HOURS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 hours of oxygen administration
Trial: 26539982
Drug: Caffeine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (5 mg∙kg‐1)
Trial: 15825785
Drug: ibuprofen/ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibuprofen/ibuprofen
Trial: 15825785
Drug: acetaminophen/acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acetaminophen/acetaminophen
Trial: 15825785
Drug: aspirin/aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aspirin/aspirin
Trial: 12424402
Drug: Topical latanoprost
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Topical latanoprost (0.005%, once daily) for 30 days (monotherapy group)
Trial: 12424402
Drug: Topical latanoprost
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Topical latanoprost (0.005%, once daily) for 180 days (combination treatment group)
Trial: 8951927
Drug: Lornoxicam (4,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam (4, 8, 16 and 20 mg)
Trial: 8951927
Drug: Morphine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (10 and 20 mg)
Trial: 8951927
Drug: Lornoxicam (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam (4 mg)
Trial: 8951927
Drug: Lornoxicam (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam (all doses)
Trial: 1657611
Drug: N‐(2‐methyl‐2‐propyl)‐3‐oxo‐4‐aza‐5 alpha‐androst‐1‐ene‐17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N‐(2‐methyl‐2‐propyl)‐3‐oxo‐4‐aza‐5 alpha‐androst‐1‐ene‐17 beta‐carboxamide (I) at doses of 5, 10, 20, 50 and 100 mg
Trial: 1657611
Drug: N‐(2‐methyl‐2‐propyl)‐3‐oxo‐4‐aza‐5 alpha‐androst‐1‐ene‐17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N‐(2‐methyl‐2‐propyl)‐3‐oxo‐4‐aza‐5 alpha‐androst‐1‐ene‐17 beta‐carboxamide (I) at 10 mg/d for 7 days
Trial: 6942835
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g deanol per day
Trial: 6942835
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g deanol per day
Trial: 24898300
Drug: Albiglutide (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albiglutide (30 mg weekly, uptitrated to 50 mg if necessary)
Trial: 24898300
Drug: Thrice-daily prandial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-daily prandial insulin lispro
Trial: 22723322
Drug: Teriparatide (56.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide (56.5 μg)
Trial: 20369761
Drug: Bupivacaine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine plus fentanyl 25 microg and a nitroglycerine patch (Group F-N)
Trial: 20369761
Drug: Bupivacaine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine plus fentanyl 25 microg and a placebo patch (Group F)
Trial: 20369761
Drug: Bupivacaine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine plus saline 0.5 ml and a nitroglycerine patch (Group B-N)
Trial: 20369761
Drug: Bupivacaine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine plus saline 0.5 ml and a placebo patch (Group B)
Trial: 17368339
Drug: sodium perborate
RxNorm normalized name: Sodium Perborate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sodium perborate + 30% hydrogen peroxide solution (SP + HP)
Trial: 17368339
Drug: sodium perborate
RxNorm normalized name: Sodium Perborate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sodium perborate + 2% chlorhexidine gel (SP + CHX)
Trial: 17368339
Drug: 37% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 37% carbamide peroxide gel (CP)
Trial: 17368339
Drug: 37% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 37% carbamide peroxide gel + 2% chlorhexidine gel (CP + CHX)
Trial: 12426215
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein (minimum of 25 g animal protein or isolated soy protein/4.2 MJ)
Trial: 12426215
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein in individuals with LDL cholesterol > or =4.14 mmol/L
Trial: 12426215
Drug: Isoflavones (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavones (50 mg/4.2 MJ)
Trial: 2045759
Drug: High intake
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intake of vitamin-K-rich vegetables for 7 days (median daily vitamin K intake 1100 micrograms)
Trial: 2045759
Drug: Phytomenadione supplementation
RxNorm normalized name: phytomenadione
DrugBank: Phylloquinone (DB01022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phytomenadione supplementation (1000 micrograms daily)
Trial: 6992570
Drug: Carbenicillin plus
RxNorm normalized name: carbenicillin
DrugBank: Carbenicillin (DB00578)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbenicillin plus gentamicin (C-G)
Trial: 6992570
Drug: Combined results
RxNorm normalized name: omega-3 acid ethyl esters (USP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined results of C-G
Trial: 6992570
Drug: C-G
RxNorm normalized name: IC-Green
DrugBank: Indocyanine green acid form (DB09374)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-G
Trial: 23721792
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis plus circumcision
Trial: 23721792
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis only
Trial: 17825687
Drug: P‐OM3 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P‐OM3 plus simvastatin 40 mg/d
Trial: 17825687
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus simvastatin 40 mg/d
Trial: 1654364
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of acyclovir five times daily for 10 days
Trial: 1654364
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of acyclovir
Trial: 23494593
Drug: Postoperative drainage
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative drainage for 5 days or drain removal when less than 50 mL/24 h
Trial: 19182619
Drug: Circumferential negative-pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circumferential negative-pressure wound therapy at -400 mmHg
Trial: 19182619
Drug: Circumferential negative-pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circumferential negative-pressure wound therapy at -125 mmHg
Trial: 19182619
Drug: Noncircumferential negative-pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noncircumferential negative-pressure wound therapy at -400 mmHg
Trial: 19182619
Drug: Noncircumferential negative-pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noncircumferential negative-pressure wound therapy at -125 mmHg
Trial: 19182619
Drug: Circumferential negative-pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circumferential negative-pressure wound therapy at -400 mmHg vs -125 mmHg
Trial: 19182619
Drug: Noncircumferential negative-pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noncircumferential negative-pressure wound therapy at -400 mmHg vs -125 mmHg
Trial: 11524060
Drug: Implanted cardioverter-defibrillator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implanted cardioverter-defibrillator therapy
Trial: 9519950
Drug: Isoniazid (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoniazid (twice weekly for 24 weeks)
Trial: 9519950
Drug: Rifampicin and
RxNorm normalized name: rifampicin and isoniazid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin and pyrazinamide (twice weekly for 8 weeks)
Trial: 21367351
Drug: Quality pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quality pharmacotherapy
Trial: 21367351
Drug: Adequate dose
RxNorm normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adequate dose of antianxiety medication
Trial: 21367351
Drug: Quality pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quality pharmacotherapy or psychotherapy
Trial: 21367351
Drug: Both quality
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both quality pharmacotherapy and psychotherapy
Trial: 18384466
Drug: Antidepressant drugs
RxNorm normalized name: MAO A Inhibitors, antidepressant drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant drugs (2-4 types) and other psychotropic drugs
Trial: 18384466
Drug: Multiple antidepressants,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple antidepressants, tricyclic antidepressants, hypnosedatives, lithium, and/or antipsychotics
Trial: 11073508
Drug: Aspirin (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (doses below 163 mg/day)
Trial: 11073508
Drug: Modified release
RxNorm normalized name: MODIFIED RELEASE CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified release formulations of aspirin
Trial: 9339405
Drug: 7.5% hypertonic
RxNorm normalized name: SODIUM CHLORIDE 7.5 g in 100 mL ORAL LIQUID [7.5% Hypertonic Saline]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5% hypertonic saline solution (HS)
Trial: 8439639
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg ranitidine b.d.s. plus 10 mg metoclopramide q.d.s.
Trial: 27863165
Drug: eHealth screening,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eHealth screening, brief intervention and referral to treatment (SBIRT)
Trial: 30595143
Drug: Yoga group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga group (twice-weekly group classes and once-weekly home practice focused on Iyengar-based yoga techniques)
Trial: 17122092
Drug: PACAP (4x12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PACAP (4x12.5 microg administered intravenously in a pulsatile fashion hourly between 2200 and 0100)
Trial: 10447050
Drug: Lidocaine i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine i.v. bolus (0.69 or 0.75 mg x kg(‐1)) under hyperbaric/hyperoxic conditions (HBO: 2.5 bar or 0.25 MPa)
Trial: 10447050
Drug: Lidocaine i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine i.v. bolus (0.69 or 0.75 mg x kg(‐1)) under normobaric conditions (NB: 1 bar or 0.1 MPa, air)
Trial: 2270529
Drug: Platelet aggregation
RxNorm normalized name: Platelet aggregation inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet aggregation (PA) measurements before treatment and yearly during a 3-year period
Trial: 24648802
Drug: D-002 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-002 (50 mg/day)
Trial: 23048011
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (triphasic estradiol and norethisterone acetate for women with intact uterus; 2 mg estradiol for women with hysterectomy)
Trial: 18763287
Drug: H pylori
RxNorm normalized name: Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H pylori IgG antibodies
Trial: 16249890
Drug: Intravenous immunoglobulins
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulins (IVIg) at 0.75 g/kg/day for 5 days
Trial: 16249890
Drug: Intravenous cyclosporin
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclosporin A (CsA) at 5 mg/kg/day for 5 days
Trial: 8941008
Drug: Cyclophosphamide and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide and cisplatin (standard therapy)
Trial: 6373094
Drug: Cephalexin 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin 1.0 g or 0.5 g daily on a bid regimen (30 mg/kg mean daily dose)